CYTOKINES AND ANTICYTOKINES IN THE PATHOGEN

Infectious Disease Clinics of North America

13, 413-426

DOI: 10.1016/s0891-5520(05)70083-0

Citation Report

#	Article	IF	Citations
1	Pathogenesis of DIC in Sepsis. Sepsis, 1999, 3, 103-109.	0.5	8
2	Infectious diseases into the next millennium. Netherlands Journal of Medicine, 1999, 55, 293-296.	0.6	0
3	Management of the Septic Patient in the Operating Room. International Anesthesiology Clinics, 2000, 38, 1-29.	0.3	0
4	Pathophysiologic basis of sepsis: Considerations for future strategies of intervention. Critical Care Medicine, 2000, 28, S4-S8.	0.4	89
5	The role of interleukin-10 in critical illness. Current Opinion in Infectious Diseases, 2000, 13, 221-226.	1.3	23
6	Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Critical Care Medicine, 2000, 28, S49-S56.	0.4	203
7	Effects of antipsychotic drugs on cytokine networks. Journal of Psychiatric Research, 2000, 34, 369-382.	1.5	176
8	Neutropenia: clinical implications and modulation. Intensive Care Medicine, 2000, 26, S103-S110.	3.9	5
9	Chloroquine Interferes with Lipopolysaccharide-Induced TNF-Î± Gene Expression by a Nonlysosomotropic Mechanism. Journal of Immunology, 2000, 165, 1534-1540.	0.4	119
10	Intrapulmonary TNF Gene Therapy Reverses Sepsis-Induced Suppression of Lung Antibacterial Host Defense. Journal of Immunology, 2000, 165, 6496-6503.	0.4	75
11	Comparable Endotoxic Properties of Lipopolysaccharides Are Manifest in Diverse Clinical Isolates of Gram-Negative Bacteria. Infection and Immunity, 2000, 68, 1899-1904.	1.0	46
12	Suppression of Macrophage Activation with CNI-1493 Increases Survival in Infant Rats with Systemic Haemophilus influenzae Infection. Infection and Immunity, 2000, 68, 5329-5334.	1.0	12
13	Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opinion on Investigational Drugs, 2000, 9, 497-514.	1.9	49
14	Systemic Inflammatory Response Syndrome. Neonatal Network: NN, 2001, 20, 21-28.	0.1	14
15	ADMISSION NEOPTERIN AND INTERLEUKIN 12 CONCENTRATIONS IN IDENTIFYING INFECTIONS IN ADULT CANCER PATIENTS. Cytokine, 2001, 13, 371-374.	1.4	4
16	Immunotherapy of sepsis. Lancet Infectious Diseases, The, 2001, 1, 165-174.	4.6	138
17	Innovative Therapies for Sepsis. BioDrugs, 2001, 15, 645-654.	2.2	19
18	Effect of corticosteroids on nuclear factor-Î°B activation and hemodynamics in late septic shock. Critical Care Medicine, 2001, 29, 1074-1077.	0.4	52

#	Article	IF	Citations
19	Activated protein C versus protein C in severe sepsis. Critical Care Medicine, 2001, 29, S69-S74.	0.4	97
20	Tolerance to lipopolysaccharide (LPS) regulates the endotoxin effects on Shiga toxin-2 lethality. Immunology Letters, 2001, 76, 125-131.	1.1	13
21	Effects of Catecholamines on the Inflammatory Response. Sepsis, 2001, 4, 159-167.	0.5	20
22	Sepsis-Induced Immunosuppression From Bad to Worse. Immunologic Research, 2001, 24, 273-288.	1.3	130
24	Evaluation of New Treatments for Meningococcal Disease. , 2001, 67, 549-586.		2
25	Systemic Inflammatory Response Syndrome, Sepsis, and Multiple Organ Dysfunction. Veterinary Clinics of North America - Small Animal Practice, 2001, 31, 1147-1162.	0.5	81
27	IL-10-Deficient Mice Demonstrate Multiple Organ Failure and Increased Mortality DuringEscherichia coliPeritonitis Despite an Accelerated Bacterial Clearance. Journal of Immunology, 2001, 166, 6323-6331.	0.4	151
28	TNF-Î± Compensates for the Impaired Host Defense of IL-1 Type I Receptor-Deficient Mice During Pneumococcal Pneumonia. Journal of Immunology, 2001, 167, 5240-5246.	0.4	140
29	Therapeutic Administration of Anti-PcrV F(abâ€²)2 in Sepsis Associated with Pseudomonas aeruginosa. Journal of Immunology, 2001, 167, 5880-5886.	0.4	123
30	Reversing Lipopolysaccharide Toxicity by Ligating the Macrophage FcÎ³ Receptors. Journal of Immunology, 2001, 166, 6861-6868.	0.4	249
31	Regulatory Role of Cytokines in Disseminated Intravascular Coagulation. Seminars in Thrombosis and Hemostasis, 2001, 27, 639-652.	1.5	141
32	Molecular Analysis of Gene-Polymorphisms Affecting the Host Response to Infection. , 2001, 67, 499-512.		0
33	Soluble cytokine receptors in biological therapy. Expert Opinion on Biological Therapy, 2002, 2, 585-605.	1.4	34
34	Anti-IL-10 Therapeutic Strategy Using the Immunomodulator AS101 in Protecting Mice from Sepsis-Induced Death: Dependence on Timing of Immunomodulating Intervention. Journal of Immunology, 2002, 169, 384-392.	0.4	119
35	D-dimer Correlates With Proinflammatory Cytokine Levels and Outcomes in Critically Ill Patients. Chest, 2002, 121, 1262-1268.	0.4	147
37	Anomalous Role of Tumor Necrosis Factor Alpha in Experimental Enterococcal Infection. Infection and Immunity, 2002, 70, 6628-6637.	1.0	17
38	First-Generation Adenovirus Vectors Shorten Survival Time in a Murine Model of Sepsis. Journal of Immunology, 2002, 169, 6539-6545.	0.4	31
39	Current Concepts of the Inflammatory Response. Refresher Courses in Anesthesiology, 2002, 30, 169-184.	0.1	2

#	Article	IF	Citations
40	Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis. Critical Care Medicine, 2002, 30, S318-S324.	0.4	50
41	Myocardial dysfunction in the patient with sepsis. Current Opinion in Critical Care, 2002, 8, 376-388.	1.6	201
42	The ability of fish oil to suppress tumor necrosis factor Î± production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor Î± production. American Journal of Clinical Nutrition, 2002, 76, 454-459.	2.2	203
43	Endothelial injury and dysfunction in ischemic acute renal failure. Critical Care Medicine, 2002, 30, S235-S240.	0.4	110
44	Peripheral Blood Mononuclear Cell Activation Induced by Leptospira interrogans Glycolipoprotein. Infection and Immunity, 2002, 70, 1677-1683.	1.0	58
45	Clinical review: Myocardial depression in sepsis and septic shock. Critical Care, 2002, 6, 500.	2.5	336
46	Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis. American Journal of Surgery, 2002, 184, S5-S10.	0.9	8
47	Symposium on â€™Nutrition in the post-genomic eraâ€™ Plenary session 4: Genetic variation and diet-related disease. Proceedings of the Nutrition Society, 2002, 61, 447-456.	0.4	71
48	Animal and human models for sepsis. Annals of Medicine, 2002, 34, 573-581.	1.5	57
49	EFFECTS OF Cl2MDP-ENCAPSULATING LIPOSOMES IN A MURINE MODEL OFPSEUDOMONAS AERUGINOSA-INDUCED SEPSIS. Journal of Liposome Research, 2002, 12, 239-257.	1.5	15
50	Antithrombotic agents in the treatment of severe sepsis. Expert Opinion on Emerging Drugs, 2002, 7, 111-139.	1.0	2
51	Redox- and oxidant-mediated regulation of interleukin-10: an anti-inflammatory, antioxidant cytokine?. Biochemical and Biophysical Research Communications, 2002, 297, 163-176.	1.0	82
52	Glucocorticoid effects on the inflammatory and clinical responses to cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2002, 16, 163-169.	0.6	96
53	Deficient transforming growth factor Î² and interleukin-10 responses contribute to the septic death of burned patients. Burns, 2002, 28, 631-637.	1.1	56
54	Liver in sepsis and systemic inflammatory response syndrome. Clinics in Liver Disease, 2002, 6, 1045-1066.	1.0	151
55	Plasminogen Activators in Inflammation and Sepsis. Vienna Clinical Weekly, 2002, 29, 80-88.	0.9	4
56	Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney International, 2002, 62, 1539-1549.	2.6	491
57	Helping to understand studies examining genetic susceptibility to sepsis. Clinical and Experimental Immunology, 2002, 127, 191-192.	1.1	7

#	Article	IF	Citations
58	Interleukin-1Î² inducesin vivotolerance to lipopolysaccharide in mice. Clinical and Experimental Immunology, 2002, 128, 221-228.	1.1	50
59	Present concepts on the inflammatory modulators with special reference to cytokines. Veterinary Research Communications, 2002, 26, 111-126.	0.6	32
60	Effects of short-chain fatty acid-supplemented total parenteral nutrition on intestinal pro-inflammatory cytokine abundance. Digestive Diseases and Sciences, 2002, 47, 2049-2055.	1.1	28
61	Anti-Septicaemic Effect of Polysaccharide from Panax ginseng by Macrophage Activation. Journal of Infection, 2002, 45, 32-38.	1.7	70
62	Genetic Polymorphisms in Sepsis and Septic Shock. Chest, 2003, 124, 1103-1115.	0.4	215
63	Serum tumour necrosis factor ? levels in severe malaria: effect of partial exchange transfusion. Intensive Care Medicine, 2003, 29, 1857-1858.	3.9	11
64	Interleukin-10 and the regulation of mitogen-activated protein kinases: are these signalling modules targets for the anti-inflammatory action of this cytokine?. Cellular Signalling, 2003, 15, 255-267.	1.7	58
65	Mast cellâ€"derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nature Immunology, 2003, 4, 1199-1205.	7.0	290
66	The cellular basis of bacterial infection. Critical Care Nursing Clinics of North America, 2003, 15, 1-11.	0.4	8
67	Coagulation dysfunction in sepsis and multiple organ system failure. Critical Care Clinics, 2003, 19, 441-458.	1.0	59
68	The Hematologic System as a Marker of Organ Dysfunction in Sepsis. Mayo Clinic Proceedings, 2003, 78, 869-881.	1.4	128
69	Suppression of Inflammatory Cytokine Production by Carbon Monoxide Involves the JNK Pathway and AP-1. Journal of Biological Chemistry, 2003, 278, 36993-36998.	1.6	332
70	Cutting Edge: Bacterial Lipoprotein Induces Endotoxin-Independent Tolerance to Septic Shock. Journal of Immunology, 2003, 170, 14-18.	0.4	82
71	Receptors, Mediators, and Mechanisms Involved in Bacterial Sepsis and Septic Shock. Clinical Microbiology Reviews, 2003, 16, 379-414.	5.7	629
72	Photoperiodic Adjustments in Immune Function Protect Siberian Hamsters from Lethal Endotoxemia. Journal of Biological Rhythms, 2003, 18, 51-62.	1.4	59
73	Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis*. Critical Care Medicine, 2003, 31, 367-373.	0.4	185
74	Clinical Trial Design and Outcomes in Patients with Severe Sepsis. Shock, 2003, 20, 295-302.	1.0	54
75	The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood, 2003, 101, 3765-3777.	0.6	1,017

#	Article	IF	Citations
76	Prostaglandin E2 mediates growth arrest in NFS-60 cells by down-regulating interleukin-6 receptor expression. Biochemical Journal, 2003, 370, 315-321.	1.7	11
77	Plasmapheresis in Sepsis. , 2004, 144, 387-394.		5
78	Drotrecogin Alfa (Activated) in an Infant with Gram-Negative Septic Shock. Journal of Intensive Care Medicine, 2004, 19, 51-55.	1.3	14
79	Cytokine Production and Monocyte HLA-DR Expression as Predictors of Outcome for Patients with Community-Acquired Severe Infections. Vaccine Journal, 2004, 11, 161-167.	2.6	158
80	A2AAdenosine Receptor Activation Improves Survival in Mouse Models of Endotoxemia and Sepsis. Journal of Infectious Diseases, 2004, 189, 1897-1904.	1.9	94
81	Investigation of the course of proinflammatory and anti-inflammatory cytokines after burn sepsis. International Journal of Clinical Practice, 2004, 58, 125-129.	0.8	32
82	Stimulation of innate immunity by susceptible and multidrug-resistant Pseudomonas aeruginosa: an in vitro and in vivo study. Clinical and Experimental Immunology, 2004, 135, 240-246.	1.1	41
83	Endothelial injury and dysfunction: Role in the extension phase of acute renal failure. Kidney International, 2004, 66, 496-499.	2.6	317
84	Endotoxin-induced liver damage in rats is minimized by ï¿½ 2 -adrenoceptor stimulation. Inflammation Research, 2004, 53, 93-99.	1.6	39
85	The role of molecular genetics in the pathogenesis and diagnosis of neonatal sepsis. Clinics in Perinatology, 2004, 31, 53-67.	0.8	20
86	Natural anticoagulant inhibitors: activated Protein C. Best Practice and Research in Clinical Haematology, 2004, 17, 161-182.	0.7	20
87	Differential regulation of Th1/Th2 in relevant tissues for sepsis pathogenesis with a Limulus anti-LPS factor-derived peptide increases survival in Gram-positive sepsis. International Immunopharmacology, 2004, 4, 1343-1351.	1.7	15
88	Drotrecogin Alfa (Activated) for the Treatment of Severe Sepsis and Septic Shock. American Journal of the Medical Sciences, 2004, 328, 205-214.	0.4	11
89	Antibiotic Treatment in a Murine Model of Sepsis: Impact on Cytokines and Endotoxin Release. Shock, 2004, 21, 115-120.	1.0	86
90	Cytokines and Growth Factors during and after a Wrestling Season in Adolescent Boys. Medicine and Science in Sports and Exercise, 2004, 36, 794-800.	0.2	35
91	Neutrophil and Small Intestinal Lymphocyte Migration After Salmonella typhimurium Infection: Impact of Fermentable Fiber. Journal of Pediatric Gastroenterology and Nutrition, 2004, 39, 73-79.	0.9	9
92	OPPOSING EFFECTS OF TUMOR NECROSIS FACTOR RECEPTOR 1 AND 2 IN SEPSIS DUE TO CECAL LIGATION AND PUNCTURE. Shock, 2005, 23, 311-318.	1.0	56
93	Animal Models of sepsis: setting the stage. Nature Reviews Drug Discovery, 2005, 4, 854-865.	21.5	673

#	Article	IF	Citations
94	Protective effect of Î²-glucan on lung injury after cecal ligation and puncture in rats. Intensive Care Medicine, 2005, 31, 865-870.	3.9	43
95	The Cholinergic Antiâ€Inflammatory Pathway Regulates the Host Response during Septic Peritonitis. Journal of Infectious Diseases, 2005, 191, 2138-2148.	1.9	358
96	SIRS, Sepsis, and MODS. , 2005, , 537-547.		0
97	Therapeutic Intervention and Targets for Sepsis. Annual Review of Medicine, 2005, 56, 225-248.	5.0	147
98	Anti-inflammatory response is associated with mortality and severity of infection in sepsis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 288, L633-L640.	1.3	80
99	Sepsis and Myocardial Depression in a Young Woman. Mayo Clinic Proceedings, 2005, 80, 810-814.	1.4	8
100	Protamine sulfate reduces the susceptibility of thermally injured mice to Pseudomonas aeruginosa infection1. Journal of Surgical Research, 2005, 123, 109-117.	0.8	10
101	Blood coagulation factors as inflammatory mediators. Blood Cells, Molecules, and Diseases, 2005, 34, 30-37.	0.6	56
102	Interleukin-1-deficient mice exhibit high sensitivity to gut-derived sepsis caused by Pseudomonas aeruginosa. Cytokine, 2005, 30, 339-346.	1.4	27
103	Sepsis and Myocardial Depression in a Young Woman. Mayo Clinic Proceedings, 2005, 80, 810-814.	1.4	10
104	Emerging drugs for the treatment of sepsis. Expert Opinion on Emerging Drugs, 2006, 11, 7-22.	1.0	3
105	Serum total antioxidant capacity reflects severity of illness in patients with severe sepsis. Critical Care, 2006, 10, R36.	2.5	111
106	CXCR4 modulates contractility in adult cardiac myocytes. Journal of Molecular and Cellular Cardiology, 2006, 41, 834-844.	0.9	78
107	Renal Ischemiaâ€“Reperfusion Injury: New Implications of Dendritic Cellâ€“Endothelial Cell Interactions. Transplantation Proceedings, 2006, 38, 670-673.	0.3	40
108	Genomic Variations and Susceptibility to Sepsis. AACN Advanced Critical Care, 2006, 17, 394-422.	0.6	14
109	Genomic Variations and Susceptibility to Sepsis. AACN Advanced Critical Care, 2006, 17, 394-422.	0.6	12
110	Safety and efficacy of affinity-purified, antiâ€“tumor necrosis factor-Î±, ovine fab for injection (CytoFab) in severe sepsis*. Critical Care Medicine, 2006, 34, 2271-2281.	0.4	68
111	Biomarker and drug-target discovery using proteomics in a new rat model of sepsis-induced acute renal failure. Kidney International, 2006, 70, 496-506.	2.6	107

#	Article	IF	Citations
112	STAT-1-mediated repression of monocyte interleukin-10 gene expressionin vivo. European Journal of Immunology, 2006, 36, 623-630.	1.6	31
113	Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma. Expert Opinion on Drug Safety, 2006, 5, 67-82.	1.0	2
114	The Duration of Hypotension before the Initiation of Antibiotic Treatment Is a Critical Determinant of Survival in a Murine Model ofEscherichia coliSeptic Shock: Association with Serum Lactate and Inflammatory Cytokine Levels. Journal of Infectious Diseases, 2006, 193, 251-258.	1.9	197
115	What Is New in Cytokine Research Related to Trauma/Critical Care. Journal of Intensive Care Medicine, 2006, 21, 63-85.	1.3	30
116	Endogenous and Exogenous Glucocorticoids in Experimental Enterococcal Infection. Vaccine Journal, 2006, 13, 349-355.	3.2	6
117	Dynamic and Transient Remodeling of the Macrophage IL-10 Promoter during Transcription. Journal of Immunology, 2006, 177, 1282-1288.	0.4	116
118	Myocardial Depression in Sepsis and Septic Shock. , 2006, , 55-73.		2
119	Selective Regulation of IL-10 Signaling and Function by Zymosan. Journal of Immunology, 2006, 176, 4785-4792.	0.4	42
120	Endogenous Interleukin-18 Improves the Early Antimicrobial Host Response in Severe Melioidosis. Infection and Immunity, 2007, 75, 3739-3746.	1.0	37
121	Toll-Like Receptors, New Horizons in Sepsis. Current Molecular Medicine, 2007, 7, 522-531.	0.6	7
123	Inhibition of Interleukin-22 Attenuates Bacterial Load and Organ Failure during Acute Polymicrobial Sepsis. Infection and Immunity, 2007, 75, 1690-1697.	1.0	69
124	Neurokinin-1 receptor antagonist treatment protects mice against lung injury in polymicrobial sepsis. Journal of Leukocyte Biology, 2007, 82, 678-685.	1.5	42
125	Effect of recombinant human activated protein C on the bactericidal activity of human monocytes and modulation of pro-inflammatory cytokines in the presence of antimicrobial agents. Journal of Antimicrobial Chemotherapy, 2007, 59, 1177-1181.	1.3	5
126	Differential Effect of Burn Injury on Fibroblasts from Wounds and Normal Skin. Plastic and Reconstructive Surgery, 2007, 119, 2101-2109.	0.7	7
127	Protective roles of hydroxyethyl starch 130/0.4 in intestinal inflammatory response and survival in rats challenged with polymicrobial sepsis. Clinica Chimica Acta, 2007, 376, 60-67.	0.5	26
128	Effect of deletion of the lpxM gene on virulence and vaccine potential of Yersinia pestis in mice. Journal of Medical Microbiology, 2007, 56, 443-453.	0.7	34
129	Interleukinâ€6 and its receptor in cancer. Cancer, 2007, 110, 1911-1928.	2.0	356
130	Resolution of Inflammation. , 2007, , 137-157.		0

#	Article	IF	Citations
131	Host Cytokine Genotype is Related to Adverse Prognosis and Systemic Inflammation in Gastro-Oesophageal Cancer. Annals of Surgical Oncology, 2007, 14, 329-339.	0.7	60
132	Interleukin-10 Gene Transfer: Prevention of Multiple Organ Injury in a Murine Cecal Ligation and Puncture Model of Sepsis. World Journal of Surgery, 2007, 31, 105-115.	0.8	19
133	Caecal ligation and puncture in the rat mimics the pathophysiological changes in human sepsis and causes multi-organ dysfunction. Metabolic Brain Disease, 2007, 22, 353-373.	1.4	56
134	Is the septic response good or bad?. Current Infectious Disease Reports, 2007, 9, 366-373.	1.3	5
135	Molecular and cellular aspects of sepsis-induced immunosuppression. Journal of Molecular Medicine, 2008, 86, 495-506.	1.7	71
136	The effect of indomethacin on systemic and renal hemodynamics in neonatal piglets during experimental endotoxemia. Pediatric Surgery International, 2008, 24, 907-911.	0.6	5
137	Altered endochondral ossification in collagen X mouse models leads to impaired immune responses. Developmental Dynamics, 2008, 237, 2693-2704.	0.8	17
138	Role of Toll-like receptor responses for sepsis pathogenesis. Immunobiology, 2008, 212, 715-722.	0.8	77
139	Butyrate and trichostatin A attenuate nuclear factor ÎºB activation and tumor necrosis factor Î± secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutrition Research, 2008, 28, 321-328.	1.3	247
140	The severity of Streptococcus pyogenes infections in children is significantly associated with plasma levels of inflammatory cytokines. Diagnostic Microbiology and Infectious Disease, 2008, 61, 165-169.	0.8	31
141	Sepsis and Cholestasis. Clinics in Liver Disease, 2008, 12, 151-172.	1.0	61
142	Contribution of IL-1 to resistance to Streptococcus pneumoniae infection. International Immunology, 2008, 20, 1139-1146.	1.8	76
143	Mechanisms of Acute Lung Injury and Repair. , 2008, , 65-71.		0
144	Early Effects of Lipopolysaccharide on Cytokine Release, Hemodynamic and Renal Function in Newborn Piglets. Neonatology, 2008, 93, 106-112.	0.9	14
145	Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Critical Care Medicine, 2008, 36, 1573-1577.	0.4	140
146	TNF-Î± and IL-6 immunohistochemistry in rat renal tissue experimentaly infected with Leptospira interrogans serovar Canicola. Journal of Venomous Animals and Toxins Including Tropical Diseases, 2008, 14, .	0.8	6
147	Effects of peritoneal lavage with lidocaine on survival of rats with fecal peritonitis. Acta Cirurgica Brasileira, 2008, 23, 42-47.	0.3	13
148	Immunological and Growth Mediator Response to Cross-Country Training in Adolescent Females. Journal of Pediatric Endocrinology and Metabolism, 2009, 22, 995-1007.	0.4	9

#	Article	IF	Citations
149	Cytokine-induced F-actin reorganization in endothelial cells involves RhoA activation. American Journal of Physiology - Renal Physiology, 2009, 296, F487-F495.	1.3	56
150	A Simple Mathematical Model of Cytokine Capture Using a Hemoadsorption Device. Annals of Biomedical Engineering, 2009, 37, 222-229.	1.3	27
151	Neutrophil elastase inhibitor (sivelestat) reduces the Levels of inflammatory mediators by inhibiting NF-kB. Inflammation Research, 2009, 58, 198-203.	1.6	37
152	Cecal ligation and puncture induced sepsis impairs host defense against Enterococcus faecium peritonitis. Intensive Care Medicine, 2009, 35, 924-932.	3.9	6
153	Interleukinâ€1 deficiency in combination with macrophage depletion increases susceptibility to Pseudomonas aeruginosa bacteremia. Microbiology and Immunology, 2009, 53, 502-511.	0.7	6
154	Therapy of autoinflammatory syndromes. Journal of Allergy and Clinical Immunology, 2009, 124, 1129-1138.	1.5	86
155	Clinical implications of cytokines in the critical-care unit. Expert Review of Cardiovascular Therapy, 2009, 7, 835-845.	0.6	3
156	Immunosuppression associated with interleukin-1R-associated-kinase-M upregulation predicts mortality in Gram-negative sepsis (melioidosis). Critical Care Medicine, 2009, 37, 569-576.	0.4	70
157	Effects of sepsis on neutrophil chemotaxis. Current Opinion in Hematology, 2010, 17, 18-24.	1.2	85
158	Early Antimicrobial Therapy in Severe Sepsis and Septic Shock. Current Infectious Disease Reports, 2010, 12, 336-344.	1.3	70
159	The Influence of Upstream ILâ€2 â€330 (T/G) and TNFâ€Î± â€308 (A/G) Polymorphisms on Glutamineâ€Supplemented Cytokine Release. Scandinavian Journal of Immunology, 2010, 72, 365-371.	1.3	4
160	Substance P in Polymicrobial Sepsis: Molecular Fingerprint of Lung Injury in Preprotachykinin-Aâ^'/â^' Mice. Molecular Medicine, 2010, 16, 188-198.	1.9	23
161	Plasma Cytokine Profiles in Preprotachykinin-A Knockout Mice Subjected to Polymicrobial Sepsis. Molecular Medicine, 2010, 16, 45-52.	1.9	13
162	Steroid Receptor Coactivator 3 Is Required for Clearing Bacteria and Repressing Inflammatory Response in Escherichia coli-Induced Septic Peritonitis. Journal of Immunology, 2010, 185, 5444-5452.	0.4	26
163	COMBINED IMMUNOSUPPRESSIVE AND ANTIBIOTIC THERAPY IMPROVES BACTERIAL CLEARANCE AND SURVIVAL OF POLYMICROBIAL SEPTIC PERITONITIS. Shock, 2010, 33, 155-161.	1.0	12
164	Treatment with Histone Deacetylase Inhibitor Attenuates MAP Kinase Mediated Liver Injury in a Lethal Model of Septic Shock. Journal of Surgical Research, 2010, 163, 146-154.	0.8	35
165	Interleukin-1Î² Mediates the Extra-Intestinal Thrombosis Associated with Experimental Colitis. American Journal of Pathology, 2010, 177, 2774-2781.	1.9	36
166	Genomics in the Evaluation and Management of Sepsis. , 2010, , 760-773.		0

#	Article	IF	Citations
167	Immunomodulatory therapy for sepsis: an update. Expert Review of Anti-Infective Therapy, 2011, 9, 1013-1033.	2.0	45
168	Ethyl Pyruvate Reduces Acute Lung Injury Via Regulation of iNOS and HO-1 Expression in Endotoxemic Rats. Journal of Surgical Research, 2011, 167, e323-e331.	0.8	38
170	Ozone Therapy and Hyperbaric Oxygen Treatment in Lung Injury in Septic Rats. International Journal of Medical Sciences, 2011, 8, 48-55.	1.1	32
171	Beneficial Effects of Hyperoncotic Albumin on Liver Injury and Survival in Peritonitis-Induced Sepsis Rats. Shock, 2011, 35, 210-216.	1.0	12
172	Innate immunity of the liver microcirculation. Cell and Tissue Research, 2011, 343, 85-96.	1.5	9
173	Selective improvement of tumor necrosis factor capture in a cytokine hemoadsorption device using immobilized antiâ€tumor necrosis factor. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2011, 96B, 127-133.	1.6	15
174	Autoinflammation: translating mechanism to therapy. Journal of Leukocyte Biology, 2011, 90, 37-47.	1.5	30
175	Molecular Biomarker of Inflammatory Response Is Associated with Rebleeding in Spontaneous Intracerebral Hemorrhage. European Neurology, 2011, 66, 322-327.	0.6	24
176	Optimizing Dendritic Cell-Based Immunotherapy: Tackling the Complexity of Different Arms of the Immune System. Mediators of Inflammation, 2012, 2012, 1-14.	1.4	42
177	The systemic inflammatory response syndrome. , 2012, , 249-263.e4.		1
178	Experimental sepsis in pigsâ€"effects of vasopressin on renal, hepatic, and intestinal dysfunction. Upsala Journal of Medical Sciences, 2012, 117, 257-263.	0.4	11
179	Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. Kidney International, 2012, 81, 363-369.	2.6	72
180	Plasma leukocyte cellâ€derived chemotaxin 2 is associated with the severity of systemic inflammation in patients with sepsis. Microbiology and Immunology, 2012, 56, 708-718.	0.7	21
181	A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock. Critical Care, 2012, 16, R31.	2.5	24
182	Sepsis: Something old, something new, and a systems view. Journal of Critical Care, 2012, 27, 314.e1-314.e11.	1.0	95
183	The Relationship Between N-acetylcysteine, Hyperbaric Oxygen, and Inflammation in a Rat Model of Acetaminophen-induced Nephrotoxicity. Inflammation, 2013, 36, 1145-1152.	1.7	14
184	Protective effects of lithium: A new look at an old drug with potential antioxidative and anti-inflammatory effects in an animal model of sepsis. International Immunopharmacology, 2013, 16, 35-40.	1.7	55
185	Biomarkers of sepsis. Critical Reviews in Clinical Laboratory Sciences, 2013, 50, 23-36.	2.7	460

#	Article	IF	Citations
186	Cytokines in Sepsis: Potent Immunoregulators and Potential Therapeutic Targetsâ€"An Updated View. Mediators of Inflammation, 2013, 2013, 1-16.	1.4	528
187	Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNFÎ± Fab fragment and human TNFÎ±. Bioscience Reports, 2013, 33, .	1.1	7
189	An alternate pathophysiologic paradigm of sepsis and septic shock. Virulence, 2014, 5, 80-97.	1.8	73
190	Protective effect of leflunomide against oxidative intestinal injury in a rodent model of sepsis. Journal of Surgical Research, 2014, 187, 610-615.	0.8	6
191	Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-Î± (TNF-Î±) using AZD9773, an anti-TNF-Î± immune Fab, in murine CLP sepsis. Inflammation Research, 2014, 63, 149-160.	1.6	18
192	Carbon Monoxide Inhibits Tenascin-C Mediated Inflammation via IL-10 Expression in a Septic Mouse Model. Mediators of Inflammation, 2015, 2015, 1-14.	1.4	17
193	Characterization of Adsorbents for Cytokine Removal from Blood in anIn VitroModel. Journal of Immunology Research, 2015, 2015, 1-11.	0.9	10
194	Peganum harmala EkstraktÄ±nÄ±n Ratlarda Ã‡ekal BaÄŸlama ve Delme ile Ä°ndÃ¼klenen Sepsiste AkciÄŸer ve BÃ¶brek Ãœzerine Koruyucu Etkileri. Kafkas Universitesi Veteriner Fakultesi Dergisi, 2015, , .	0.0	0
195	Gemfibrozil attenuates the inflammatory response and protects rats from abdominal sepsis. Experimental and Therapeutic Medicine, 2015, 9, 1018-1022.	0.8	21
196	Systemic Inflammatory Response Syndrome. , 2015, , 30-34.		11
197	The Growing Spectrum of Anti-Inflammatory Interleukins and Their Potential Roles in the Development of Sepsis. Journal of Interferon and Cytokine Research, 2015, 35, 242-251.	0.5	26
198	Interleukin-1 Gene Cluster Polymorphisms and its Haplotypes may Predict the Risk to Develop Cervical Cancer in Tunisia. Pathology and Oncology Research, 2015, 21, 1101-1107.	0.9	13
199	The duality of chemokines in heart failure. Expert Review of Clinical Immunology, 2015, 11, 523-536.	1.3	4
200	Optimizing Antimicrobial Therapy of Sepsis and Septic Shock: Focus on Antibiotic Combination Therapy. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 154-166.	0.8	49
201	Cellular and viral microRNAs in sepsis: mechanisms of action and clinical applications. Cell Death and Differentiation, 2016, 23, 1906-1918.	5.0	46
202	Resveratrol alleviates sepsis-induced myocardial injury in rats by suppressing neutrophil accumulation, the induction of TNF-Î± and myocardial apoptosis via activation of Sirt1. Molecular Medicine Reports, 2016, 14, 5297-5303.	1.1	22
203	Enhanced Neuroprotection of Minimally Invasive Surgery Joint Local Cooling Lavage against ICH-induced Inflammation Injury and Apoptosis in Rats. Cellular and Molecular Neurobiology, 2016, 36, 647-655.	1.7	15
204	Serum oxygen radical activity and total antioxidation capacity are related with severities of surgical patient with sepsis: Prospective pilot study. Journal of Critical Care, 2017, 39, 131-136.	1.0	10

#	Article	IF	Citations
205	The characteristics and impact of source of infection on sepsis-related ICU outcomes. Journal of Critical Care, 2017, 41, 170-176.	1.0	42
206	Role of HMGB1 translocation to neuronal nucleus in rat model with septic brain injury. Neuroscience Letters, 2017, 645, 90-96.	1.0	5
207	Pediatric Sepsis Markers: Interleukins and Others. Journal of Child Science, 2017, 07, e96-e102.	0.1	0
208	Enhanced pulmonary bioavailability of curcumin by some common excipients and relative therapeutic effects on sepsis-induced acute lung injury in rats. Journal of Drug Delivery Science and Technology, 2017, 41, 231-238.	1.4	2
209	Are cytokines and chemokines suitable biomarkers for Takayasu arteritis?. Autoimmunity Reviews, 2017, 16, 1071-1078.	2.5	54
210	Cytokines and Inflammatory Response in the Fetus and Neonate. , 2017, , 1241-1254.e4.		16
211	The predictive value of plasma cytokines on gastroesophageal anastomotic leakage at an early stage in patients undergoing esophagectomy. Journal of Thoracic Disease, 2017, 9, 2544-2550.	0.6	5
212	MiocardiopatÃa sÃ©ptica en pacientes pediÃ¡tricos: fisiopatologÃa y presentaciÃ³n clÃnica. Acta Colombiana De Cuidado Intensivo, 2018, 18, 179-189.	0.1	1
213	Rapid negative inotropic effect induced by TNF-Î± in rat heart perfused related to PKC activation. Cytokine, 2018, 107, 65-69.	1.4	13
214	Inflammatory and coagulatory parameters linked to survival in critically ill children with sepsis. Annals of Intensive Care, 2018, 8, 111.	2.2	18
215	Plasma Antioxidant Potential at Admission is Associated with Length of ICU Stay in Child with Sepsis: A Pilot Study. Fetal and Pediatric Pathology, 2018, 37, 348-358.	0.4	4
216	The Systemic Inflammatory Response Syndrome. , 2018, , 205-220.e4.		20
217	Effect of taxifolin on methanol-induced oxidative and inflammatory optic nerve damage in rats. Cutaneous and Ocular Toxicology, 2019, 38, 384-389.	0.5	15
218	Acute phase protein, Î± â€“ 1- acid glycoprotein (AGP-1), has differential effects on TLR-2 and TLR-4 mediated responses. Immunobiology, 2019, 224, 672-680.	0.8	12
219	Making sense of gut feelings in the traumatic brain injury pathogenesis. Neuroscience and Biobehavioral Reviews, 2019, 102, 345-361.	2.9	28
220	The Effects of Two Different Burn Dressings on Serum Oxidative Stress Indicators in Children with Partial Burn. Journal of Burn Care and Research, 2019, 40, 444-450.	0.2	6
221	Shengjiang Powder ameliorates myocardial injury in septic rats by downregulating the phosphorylation of P38-MAPK. Journal of Biosciences, 2019, 44, 1.	0.5	5
222	Angiopoietin 1 influences ischemic reperfusion renal injury via modulating endothelium survival and regeneration. Molecular Medicine, 2019, 25, 5.	1.9	17

#	Article	IF	Citations
223	Interleukinâ€4 â€590C/T gene polymorphism in Egyptian children with acute lower respiratory infection: A multicenter study. Pediatric Pulmonology, 2019, 54, 297-302.	1.0	5
224	New Biomarkers of Sepsis with Clinical Relevance. , 0, , .		5
225	Anti-inflammatory effects of methanol extracts from the Antarctic lichen, Amandinea sp. in LPS-stimulated raw 264.7 macrophages and zebrafish. Fish and Shellfish Immunology, 2020, 107, 301-308.	1.6	14
226	Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVIDâ€19. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1515-1519.	0.7	66
227	The effects of chrysin on lipopolysaccharideâ€induced sepsis in rats. Journal of Food Biochemistry, 2020, 44, e13359.	1.2	22
228	Lysophosphatidylcholine acyltransferase 2 (LPCAT2) co-localises with TLR4 and regulates macrophage inflammatory gene expression in response to LPS. Scientific Reports, 2020, 10, 10355.	1.6	25
229	Interleukin Iâ€1B gene polymorphism in Tunisian patients with chronic hepatitis B infection: Association with replication levels. Microbiology and Immunology, 2020, 64, 512-519.	0.7	2
230	Diagnostische Grundlagen. , 2021, , 13-36.		0
231	The Central and Autonomic Nervous Systems: Essential Regulators of the Immune Response. , 2005, , 421-433.		2
232	Innate Immune Responses in Ventilator-Associated Pneumonia. , 2013, , 185-212.		4
233	Coagulation and Fibrinolysis During Endotoxemia and Gram-Negative Sepsis. , 2001, , 423-436.		1
234	Endotoxemia in Healthy Subjects as a Human Model of Inflammation. , 2002, , 335-357.		9
235	Cytokines and Inflammatory Response in the Fetus and Neonate. , 2004, , 1555-1572.		3
236	The systemic inflammatory response syndrome. , 2007, , 292-309.		2
237	Cytokines and Inflammatory Response in the Fetus andÂNeonate. , 2011, , 1652-1671.		1
238	The use of granulocyte colony-stimulating factor in critically ill patients. Critical Care Medicine, 2000, 28, 3758-3759.	0.4	2
239	Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. Shock, 2004, 21, 115-20.	1.0	39
240	The Effect of Cholinesterase Activity on the Diagnosis and Prognosis of Sepsis. Clinical Medicine Research, 2016, 5, 28.	0.0	2

#	Article	IF	Citations
241	Modulating macrophage function with IgG immune complexes. Journal of Endotoxin Research, 2002, 8, 477-481.	2.5	42
242	IRAK-M Regulates Chromatin Remodeling in Lung Macrophages during Experimental Sepsis. PLoS ONE, 2010, 5, e11145.	1.1	47
243	Advances in Treating Patients With Severe Sepsis. Critical Care Nurse, 2003, 23, 16-29.	0.5	31
244	Resistance to lipopolysaccharide-induced endotoxic shock in heterozygous Zfp191 gene-knockout mice. Genetics and Molecular Research, 2011, 10, 3712-3721.	0.3	4
245	Inflammation: the foundation of diseases and disorders. A review of phytomedicines of South African origin used to treat pain and inflammatory conditions.. African Journal of Biotechnology, 2007, 6, 2868-2885.	0.3	155
246	Decreased levels of alpha-1-acid glycoprotein are related to the mortality of septic patients in the emergency department. Clinics, 2013, 68, 1134-1139.	0.6	19
247	Pro-Inflammatory Cytokines: Double-Edged Swords in the Pathogenesis of Bacterial Infection. Update in Intensive Care and Emergency Medicine, 2002, , 146-158.	0.6	0
248	SIRS, sepsis, and MODS. , 2003, , 1047-1056.		0
249	Modulation of the innate immune response during respiratory tract infections. , 2003, , 1231-1238.		0
250	Sepsis: EtiologÃa, Manifestaciones ClÃnicas y DiagnÃ³stico. MEDICRIT Revista De Medicina CrÃtica, 2005, 2, .	0.1	2
251	Anesthesia for Children with Burns. , 2006, , 975-990.		0
252	Clinical Presentations of Systemic Inflammatory Response in Term and Preterm Infants. , 2008, , 208-216.		0
253	Sepsis and the Genomic Revolution. , 2009, , 1362-1374.		0
254	La brÃ»lure. , 2010, , 37-52.		0
255	Immunoglobulins in Sepsis. , 2011, , 235-242.		4
256	Ulinastatin and Septic Cardiac Dysfunction. , 0, , .		0
257	Protective effect of hydrogen-lactated Ringer's solution against extensive burn-induced intestine injury in rats after delayed fluid resuscitation. Academic Journal of Second Military Medical University, 2012, 32, 170-174.	0.0	0
261	HLA-DR (cellular and soluble) and inflammatory serum markers in patients after trauma: can they predict outcome?. Chirurgia (Turin), 2019, 32, .	0.0	0

#	Article	IF	Citations
262	Effect of Rutin on Cytarabine-Associated Pulmonary Oedema and Oxidative Stress in Rats. Anais Da Academia Brasileira De Ciencias, 2020, 92, e20190261.	0.3	4
263	Precision medicine in sepsis and septic shock: From omics to clinical tools. World Journal of Critical Care Medicine, 2022, 11, 1-21.	0.8	20
264	Shengjiang Powder ameliorates myocardial injury in septic rats by downregulating the phosphorylation of P38-MAPK. Journal of Biosciences, 2019, 44, .	0.5	5
265	Blood purification in sepsis and COVID-19: whatÂ´s new in cytokine and endotoxin hemoadsorption. Journal of Anesthesia, Analgesia and Critical Care, 2022, 2, .	0.5	6
270	Organ Dysfunctions during Severe Sepsis and Septic-Like Syndromes: Epidemiology, Classification, and Mechanisms. , 0, , 57-76.		1
271	Comparing the Cytokine Storms of COVID-19 and Pandemic Influenza. Journal of Interferon and Cytokine Research, 2022, 42, 369-392.	0.5	9
272	Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients. Critical Care, 2022, 26, .	2.5	19
273	Obesity, inflammation, and cancer in dogs: Review and perspectives. Frontiers in Veterinary Science, 0, 9, .	0.9	6
274	Exosomeâ€Based Mitochondrial Delivery of circRNA mSCAR Alleviates Sepsis by Orchestrating Macrophage Activation. Advanced Science, 2023, 10, .	5.6	11